Close Menu

NEW YORK (GenomeWeb) – In its effort to spur adoption of pharmacogenetic testing in mainstream care, Genelex recently published a randomized-controlled pilot study that it hopes will improve the reimbursement prospects of its test, and spun out its analytics and clinical decision support tool YouScript as an independent business.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.